Martínez-Abundis E, Barrera-Durán C, González-Ortiz M, Hernández-Salazar E

Language: Spanish
References: 28
Page: 88-95
PDF size: 100.80 Kb.

ABSTRACT

Introduction: Mixed dyslipidemia accelerates atherosclerosis and leads to cardiovascular disease and death. Non-soluble fibers such as inulin have been shown to have an effect on dyslipidemia. Aim: To assess the effect of the combination of simvastatin plus inulin in comparison with simvastatin plus ezetimibe in mixed dyslipidemia. Material and methods: A randomized, double-blind, clinical trial with parallel control group was performed in 60 patients with mixed dyslipidemia, without drug treatment or failure to statins and lifestyle changes. Intervention: simvastatin (20 mg), inulin from agave (7 g) and placebo of ezetimibe, or simvastatin (20 mg), ezetimibe (10 mg) and placebo of inulin from agave, daily at night, for 12 weeks. Results: Both groups decreased total cholesterol (235 ± 29 vs. 182 ± 42 mg/dl; p = 0.001 and 236 ± 31 vs. 160 ± 48 mg/dl; p ‹ 0.001), low-density lipoprotein cholesterol (141 ± 32 vs. 99 ± 34 mg/dl; p ‹ 0.001 and 149 ± 35 vs. 89 ± 43 mg/dl; p ‹ 0.001) and triglycerides (284 ± 117 vs. 214 ± 137 mg/dl; p = 0.027 and 241 ± 81 vs. 180 ± 68 mg/dl; p ‹ 0.001), respectively, for simvastatin plus inulin and simvastatin plus ezetimibe. Conclusion: The combination of simvastatin plus inulin reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides the same as simvastatin plus ezetimibe.

REFERENCES

1. Grundy SM, Howard B, Smith JS, Eckel R, Redberg R, Bonow RO. AHA conference proceedings prevention conference VI: diabetes and cardiovascular disease executive summary. Circulation. 2002;105:2231-9.

2. Cottrel DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol. 2003;18:301-8.

3. Stone N, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1-S45.

4. Ray KK, Cannon CP, Braunwald E. Recent trials of lipid lowering. Int J Clin Pract. 2007;61:1145-59.

5. Bruckert E. New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97:59-66.

6. Kosoglu T, Statkevich P, Johnson-Levonas AO, Paolini, J, Bergman A, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467-94.

7. Dujovne CA, Ettinger MP, McNeer JF, et al.; for the Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-7.

8. Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Am Pharmacother. 2003;37:839-48.

9. Anderson JW, Hanna TJ. Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular disease. J Nutr. 1999;129:1457S-66S.

10. Delzenne NM, Williams CM. Prebiotics and lipid metabolism. Curr Opin Lipidol. 2002;13:61-7.

11. Balcázar Muñoz BR, Martínez-Abundis E, González-Ortiz M. Efecto de la administración oral de inulina sobre el perfil de lípidos y la sensibilidad a la insulina en individuos con obesidad y dislipidemia. Rev Med Chile. 2003;131:597-604.

12. Delzenne NM, Kok NN. Biochemical basis of oligofructose-induced hypolipidemia in animal models. J Nutr. 1999;129:1467S-70S.

13. Davison MH, Maki KC. Effects of dietary inulin on serum lipids. J Nutr. 1999;129:1474S-77S.

14. Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989;26:115-21.

15. Grundy SM, Cleeman JI, Bairey Merz NC, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.

16. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012-22.

17. Davis HR, Veltri EP. Review. Zetia: inhibition of Niemman Pick C1 Like1 (NCP1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007;14:99-108.

18. Ara T, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Asses. 2008;12(21).

19. González-Ortiz M, Martínez-Abundis E, Kam-Ramos AM, Henández-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther. 2006;20:143-6.

20. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372: 2387-97.

21. Becker JD, Gordon YR, Morris PB, et al. Simvastatin vs. therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758-64.

22. Dehghan P, Gargari BP, Asgharijafarabadi M. Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promotion Perspectives. 2013;3:55-63.

23. Williams CM. Effects of inulin on lipid parameters in humans. J Nutr. 1999;129:1471S-73S.

24. Jackson KG, Taylor GRJ, Clohessy AM, Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br J Nutr. 1999;82:23-30.

25. Urías-Silvas JE, Cani Patrice D, Delmée E, Neyrinck A, López MG, Delzenne NM. Physiological effects of dietary fructans extracted from agave tequilana Gto. and dasylirion spp. BJN. 2008;99:254-61.

26. Anderson JW, Hanna TJ. Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular disease. J Nutr. 1999;129:1457S-66S.

27. Thies F, McGarry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003;361:477-85.

28. Kelly G. Inulin-type prebiotics: a review. (Part 2). Altern Med Rev. 2009;14:36-55.